A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan

Anticancer Research

Volumn 26, Issue 6 A, 2006, Pages 4015-4018

  Fujimoto, Katsunada ^a   Tomonaga, Masamichi ^a   Goto, Shigenori ^b  

^a Fukuoka Medical Clinic   (Japan)

^b Seta Clinic   (Japan)

Author keywords

Adoptive immunotherapy; Lentinan; Lymph node metastases; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CD3 ANTIGEN; INTERLEUKIN 2; LENTINAN; PACLITAXEL; TEGAFUR;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOTHERAPY; LABORATORY TEST; LYMPH NODE; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR BIOPSY;

AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTINAN; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 33845954915     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232): 802-807, 2000.
2. Erratum in: Lancet 356(9242): 1690, 2000.
3. Takayama T and Makuuchi M: Prevention of hepatocellular carcinoma recurrence: actuality and perspectives. Hepatogastroenterology 49(43): 87-90, 2002
4. Taguchi T: Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1: 333-349, 1987.
5. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K and Kakizoe T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47: 73-78, 1993.
6. Ikarashi H, Fujita K, Takakuwa K, Kodama S, Tokunaga A, Takahashi T and Tanaka K: Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 54: 190-196, 1994.
7. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T and Tanaka K: Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1: 501-507, 1995.
8. Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K and Egawa K: Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res 22: 2461-2464, 2002.
9. Chihara G, Maeda Y, Hamuro J, Sasaki T and Fukuoka F: Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222: 687-688, 1969.
10. Chihara G, Hamuro J, Maeda Y, Arai Y and Fukuoka F: Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 30: 2776-2781, 1970.
11. Zakany J, Chihara G and Fachet J: Effect of lentinan on the production of migration inhibitory factor induced by syngeneic tumor in mice. Int J Cancer 26: 783-788, 1980.
12. Suga T, Shiio T, Maeda Y and Chihara G: Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44: 5132-5137, 1984.
13. Thornton BP, Vetvicka V, Pitman M, Goldman RC and Ross GD: Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156: 1235-1246, 1996.
14. Brown GD and Gordon S: Immune recognition. A new receptor for beta-glucans. Nature 413: 36-37, 2001.
15. Murata Y, Shimamura T, Tagami T, Takatsuki F and Hamuro J: The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int Immunopharmacol 2: 673-689, 2002.